{"slideshow_credits": null, "snippet": "The transaction is expected to improve the British drug maker\u2019s pipeline of treatments for cardiovascular and metabolic diseases.", "abstract": "British drug maker AstraZeneca agrees to buy ZS Pharma for $2.7 billion.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Chad", "role": "reported", "lastname": "BRAY", "rank": 1, "organization": ""}], "original": "By CHAD BRAY"}, "web_url": "http://www.nytimes.com/2015/11/07/business/dealbook/astrazeneca-agrees-to-buy-zs-pharma-for-2-7-billion.html", "lead_paragraph": "The transaction is expected to improve the British drug maker\u2019s pipeline of treatments for cardiovascular and metabolic diseases.", "headline": {"main": "AstraZeneca Agrees to Buy ZS Pharma for $2.7 Billion", "print_headline": "Business Briefing; AstraZeneca Agrees to Buy ZS Pharma for $2.7 Billion"}, "_id": "563c704038f0d86bed6b712d", "word_count": "348", "multimedia": [], "pub_date": "2015-11-07T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "AstraZeneca PLC", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "ZS Pharma Inc.", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "4"}, {"name": "organizations", "value": "Food and Drug Administration", "is_major": "N", "rank": "5"}, {"name": "glocations", "value": "Great Britain", "is_major": "N", "rank": "6"}, {"name": "glocations", "value": "California", "is_major": "N", "rank": "7"}, {"name": "organizations", "value": "Pfizer Inc", "is_major": "N", "rank": "8"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}